FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117458518> ?p ?o ?g. }

• W2117458518 endingPage "9" @default.
• W2117458518 startingPage "1642" @default.
• W2117458518 abstract "The goals of this clinical trial involving postmenopausal women with metastatic breast cancer were to: (a) examine the effects of letrozole on tamoxifen (TAM) pharmacokinetics; (b) examine estrogen suppression in patients receiving TAM plus letrozole; and (c) evaluate tolerability, toxicity, objective response, and time to progression for the combination. Postmenopausal women with measurable or evaluable metastatic breast cancer received TAM (20 mg daily) for 6 weeks, and then letrozole (2.5 mg daily) was added. To examine for any effect of letrozole on the levels of TAM and two metabolites [N-desmethyl-TAM and 4-hydroxy-TAM], serum samples were obtained at 6, 12, 18, and 24 weeks. To examine for aromatase inhibition, serum samples were obtained before treatment and at 6, 12, 18, and 24 weeks for estradiol, estrone (E1) E1 sulfate, and sex hormone-binding globulin. A total of 34 patients were entered on this trial, and 23 patients were still on study at week 24, 18 of whom had blood samples available at both week 6 and week 24. The 95% confidence interval for the mean difference between levels at week 24 and levels at week 6 was -34 to 15 ng/ml for TAM, -35 to 45 ng/ml for N-desmethyl-TAM, and -1 to 2 for 4-hydroxy-TAM. For estradiol, a significant decrease (median, 88.5%; range, 73.7-95.2%) was identified after 6 weeks of letrozole, which was maintained for an additional 12 weeks. Similar significant reductions were identified for E1. E1 sulfate levels increased after 6 weeks of TAM alone but then decreased significantly after the addition of letrozole. Sex hormone-binding globulin levels were significantly elevated after 6 weeks of TAM alone and remained elevated after the addition of letrozole. Six of the 34 patients (17.6%) achieved an objective response (95% confidence interval, 6.8-34.5%), with a median time to disease progression of 7.6 months. There was no indication of a systematic decrease in TAM, N-desmethyl-TAM, or 4-hydroxy-TAM after the additional of letrozole. Estrogen suppression induced by letrozole was substantial despite the concomitant administration of TAM. The antitumor effect of TAM plus letrozole was less than expected." @default.
• W2117458518 created "2016-06-24" @default.
• W2117458518 creator A5008767553 @default.
• W2117458518 creator A5020035024 @default.
• W2117458518 creator A5035359387 @default.
• W2117458518 creator A5040261194 @default.
• W2117458518 creator A5049919852 @default.
• W2117458518 creator A5060700606 @default.
• W2117458518 creator A5065306642 @default.
• W2117458518 creator A5082661564 @default.
• W2117458518 creator A5082914796 @default.
• W2117458518 creator A5083904553 @default.
• W2117458518 date "1999-07-01" @default.
• W2117458518 modified "2023-09-23" @default.
• W2117458518 title "Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer." @default.
• W2117458518 cites W1561074806 @default.
• W2117458518 cites W1934173384 @default.
• W2117458518 cites W1964176572 @default.
• W2117458518 cites W1972696758 @default.
• W2117458518 cites W1979300931 @default.
• W2117458518 cites W2001664184 @default.
• W2117458518 cites W2002041504 @default.
• W2117458518 cites W2006782216 @default.
• W2117458518 cites W2039631399 @default.
• W2117458518 cites W2043843488 @default.
• W2117458518 cites W2056166929 @default.
• W2117458518 cites W2063069513 @default.
• W2117458518 cites W2065244797 @default.
• W2117458518 cites W2090691058 @default.
• W2117458518 cites W2157681187 @default.
• W2117458518 cites W2167089425 @default.
• W2117458518 cites W2167514715 @default.
• W2117458518 cites W2171423946 @default.
• W2117458518 cites W2341178074 @default.
• W2117458518 cites W2433539343 @default.
• W2117458518 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10430063" @default.
• W2117458518 hasPublicationYear "1999" @default.
• W2117458518 type Work @default.
• W2117458518 sameAs 2117458518 @default.
• W2117458518 citedByCount "16" @default.
• W2117458518 countsByYear W21174585182012 @default.
• W2117458518 countsByYear W21174585182013 @default.
• W2117458518 countsByYear W21174585182018 @default.
• W2117458518 countsByYear W21174585182021 @default.
• W2117458518 crossrefType "journal-article" @default.
• W2117458518 hasAuthorship W2117458518A5008767553 @default.
• W2117458518 hasAuthorship W2117458518A5020035024 @default.
• W2117458518 hasAuthorship W2117458518A5035359387 @default.
• W2117458518 hasAuthorship W2117458518A5040261194 @default.
• W2117458518 hasAuthorship W2117458518A5049919852 @default.
• W2117458518 hasAuthorship W2117458518A5060700606 @default.
• W2117458518 hasAuthorship W2117458518A5065306642 @default.
• W2117458518 hasAuthorship W2117458518A5082661564 @default.
• W2117458518 hasAuthorship W2117458518A5082914796 @default.
• W2117458518 hasAuthorship W2117458518A5083904553 @default.
• W2117458518 hasConcept C112705442 @default.
• W2117458518 hasConcept C121608353 @default.
• W2117458518 hasConcept C126322002 @default.
• W2117458518 hasConcept C143998085 @default.
• W2117458518 hasConcept C197934379 @default.
• W2117458518 hasConcept C2775930923 @default.
• W2117458518 hasConcept C2777164284 @default.
• W2117458518 hasConcept C2777176818 @default.
• W2117458518 hasConcept C2778375690 @default.
• W2117458518 hasConcept C2778504769 @default.
• W2117458518 hasConcept C2778656385 @default.
• W2117458518 hasConcept C2778812593 @default.
• W2117458518 hasConcept C2779149875 @default.
• W2117458518 hasConcept C530470458 @default.
• W2117458518 hasConcept C71924100 @default.
• W2117458518 hasConceptScore W2117458518C112705442 @default.
• W2117458518 hasConceptScore W2117458518C121608353 @default.
• W2117458518 hasConceptScore W2117458518C126322002 @default.
• W2117458518 hasConceptScore W2117458518C143998085 @default.
• W2117458518 hasConceptScore W2117458518C197934379 @default.
• W2117458518 hasConceptScore W2117458518C2775930923 @default.
• W2117458518 hasConceptScore W2117458518C2777164284 @default.
• W2117458518 hasConceptScore W2117458518C2777176818 @default.
• W2117458518 hasConceptScore W2117458518C2778375690 @default.
• W2117458518 hasConceptScore W2117458518C2778504769 @default.
• W2117458518 hasConceptScore W2117458518C2778656385 @default.
• W2117458518 hasConceptScore W2117458518C2778812593 @default.
• W2117458518 hasConceptScore W2117458518C2779149875 @default.
• W2117458518 hasConceptScore W2117458518C530470458 @default.
• W2117458518 hasConceptScore W2117458518C71924100 @default.
• W2117458518 hasIssue "7" @default.
• W2117458518 hasLocation W21174585181 @default.
• W2117458518 hasOpenAccess W2117458518 @default.
• W2117458518 hasPrimaryLocation W21174585181 @default.
• W2117458518 hasRelatedWork W1040971774 @default.
• W2117458518 hasRelatedWork W1491737910 @default.
• W2117458518 hasRelatedWork W1918073772 @default.
• W2117458518 hasRelatedWork W1990479899 @default.
• W2117458518 hasRelatedWork W2032922414 @default.
• W2117458518 hasRelatedWork W2040234260 @default.
• W2117458518 hasRelatedWork W2117458518 @default.
• W2117458518 hasRelatedWork W2136099166 @default.
• W2117458518 hasRelatedWork W2161327328 @default.

• next